CAS No.10212-25-6,2,2'-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride Suppliers

Products Categories

Pharmaceutical (126)
Organic Chemicals (39)
Others (18)
Reagent (7)
Materials (2)
Plant Extract (1)

Basic Information

Molecular Structure:
CAS No.:	10212-25-6
Name:	2,2'-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride

Formula:	C₉H₁₁N₃O₄^.HCl
Molecular Weight:	261.665
Synonyms:	Ancitabine hydrochloride (JAN);2, 2-Anhydroarabinosylcytosine hydrochloride;Cytosine, 1beta-D-arabinofuranosyl-2,2-anhydro-, hydrochloride;Cyclo-cmp hydrochloride;CycloCMP hydrochloride;2,2-Anhydroarabinosylcytosine hydrochloride;O2,2-Cyclocytidine, monohydrochloride;1-beta-D-Arabinofuranosylcytosine, 2,2-anhydro-, hydrochloride;1beta-D-Arabinofuranosylcytosine, 2,2-anhydro-, hydrochloride;2,2-O-Cyclocytidine hydrochloride;2, 2-O-Cyclocytidine hydrochloride;2,2-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride;Cyclocytidine hydrochloride;2,2-Anhydrocytarabine hydrochloride;O-2,2-Cyclocytidine monohydrochloride;2,2-Cyclocytidine hydrochloride;6H-Furo(2,3:4,5)oxazolo(3,2-a)-pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, monohydrochloride, stereoisomer;1.beta.-D-Arabinofuranosylcytosine, 2, 2-anhydro-, hydrochloride;2, 2-Anhydro-1.beta.-D-arabinofuranosylcytosine hydrochloride;OCTD hydrochloride;2,2-Cyclocytidine, monohydrochloride;2,2-Anhydroaracytidine hydrochloride;Cytosine, 1.beta.-D-arabinofuranosyl-2,2-anhydro-, hydrochloride;2,2'-anhydrocytidine hydrochloride;CyclocytidiniHydrochlorinum;
EINECS:	233-515-6
Density:	2.01 g/cm³
Melting Point:	269-270 °C (dec.)(lit.)
Boiling Point:	442 °C at 760 mmHg
Flash Point:	221.1 °C
Appearance:	white fine crystalline powder
Safety:	24/25
PSA:	100.59000
LogP:	-0.72410

Total:146 Page 1 of 4 1 2 3 4 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 10212-25-6

Specification

The Cyclocytidine hydrochloride with the cas number 79559-97-0, is also called (1)1-beta-D-Arabinofuranosylcytosine, 2,2'-anhydro- ,hydrochloride; (2)1beta-D-Arabinofuranosylcytosine, 2,2'-anhydro-, hydrochloride ; (3)2,2'-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride ; (4)2,2'-Anhydro-1beta-D-arabinofuranosylcytosine hydrochloride ; (5)2,2'-Anhydroarabinosylcytosine hydrochloride ; (6)2,2'-Anhydroaracytidine hydrochloride ; (7)2,2'-Anhydrocytarabine hydrochloride ; (8)2,2'-Anhydrocytidine hydrochloride ; (9)2,2'-Cyclocytidine hydrochloride ; (10)2,2'-Cyclocytidine, monohydrochloride ; (11)2,2'-O-Cyclocytidine hydrochloride ; (12)Ancitabin HCl ; (13)Ancitabin hydrochlorid ; (14)(-)-Cyclocytidine hydrochloride ; (15)Cyclo-cmp hydrochloride ; (16)Cyclocytidine ; (17)Cyclocytidine hydrochloride ; (18)Cytosine, 1-beta-D-arabinofuranosyl-2,2'-anhydro-, hydrochloride; (19)Cytosine, 1beta-D-arabinofuranosyl-2,2'-anhydro-, hydrochloride; (20)O-2,2'-Cyclocytidine monohydrochloride. It belongs to the following product categories:(1)API intermediates; (2)Biochemistry; (3)Nucleosides and their analogs; (4)Nucleosides, Nucleotides & Related Reagents

Properties of Cyclocytidine hydrochloride are: (1)ACD/LogP: -2.30 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): -4.24 ; (4)ACD/LogD (pH 7.4): -3.25 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 1 ; (7)ACD/KOC (pH 5.5): 1 ; (8)ACD/KOC (pH 7.4): 1 ; (9)#H bond acceptors: 7 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 3 ; (12)Polar Surface Area: 64.88 Å² ; (13)Flash Point: 209.1 °C ; (14)Enthalpy of Vaporization: 78.11 kJ/mol ; (15)Boiling Point: 422.2 °C at 760 mmHg ; (16)Vapour Pressure: 6.77E-09 mmHg at 25°C

The Cyclocytidine hydrochloride appears to be white fine crystalline powder. This product translates into cytarabine in the body, and has a similar function to similar. It is cell cycle specific agent, mainly act on in S phase. It is clinical used for all kinds of acute leukemia, acute myelogenous leukemia, and also have good effect on meningeal leukemia. Cyclocytidine hydrochloride is used in the treatment of herpes simplex virus keratitis in ophthalmology. Usage: intravenous injection, adult 200mg ~ 600mg/times, once a day, succession of 5-7 days as a course of treatment. Muscle injection or oral doses, dose is similar with static injection.

You can still convert the following datas into molecular structure :
1. SMILES: Cl.O2/C1=N/C(=[N@H])/C=C\N1[C@@H]3O[C@@H]([C@@H](O)[C@H]23)CO
2. InChI: InChI=1/C9H11N3O4.ClH/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8;/h1-2,4,6-8,10,13-14H,3H2;1H/b10-5+;/t4-,6-,7+,8-;/m1./s1

The Cyclocytidine hydrochloride toxic data can be showed in the following sheet.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	344mg/kg (344mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING	Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 353, 1974.
monkey	LD50	intravenous	1045mg/kg (1045mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS	Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 353, 1974.
mouse	LD50	intraperitoneal	2528mg/kg (2528mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	800mg/kg (800mg/kg)		Drugs in Japan Vol. 6, Pg. 55, 1982.
mouse	LD50	oral	> 7gm/kg (7000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
mouse	LD50	subcutaneous	4050mg/kg (4050mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat	LD50	intraperitoneal	3800mg/kg (3800mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat	LD50	intravenous	820mg/kg (820mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat	LD50	oral	> 7gm/kg (7000mg/kg)		Drugs in Japan Vol. -, Pg. 86, 1990.
rat	LD50	subcutaneous	> 5500mg/kg (5500mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
women	TDLo	subcutaneous	120mg/kg (120mg/kg)	VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Cancer Treatment Reports. Vol. 62, Pg. 455, 1978.